Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
NEJM 382:9-19,81, Amarenco, P.,et al, 2020
Cholesterol Lowering and Prevention of Stroke
Stroke 50:537-541, Hackam, D.G. & Hegele, R.A., 2019
Clinicopathologic Conference, Statin-Associated Autoimmune Myopathy
NEJM 381:275-283, Case 22-2019, 2019
Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Anti-HMGCR Autoantibodies in European Patients with Autoimmune Necrotizing Myopathies
Medicine 93:150-157, Allenbach, Y.,et al, 2014
Aggressive Medical Therapy Alone is Not Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2955-2956, Brown, M.M., 2013
Aggressive Medical Therapy Alone is Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2957-2958, Chaturvedi, S.,et al, 2013
Reduction in Early Stroke Risk in Carotid Stenosis with Transient Ischemic Attack Associated with Statin Treatment
Stroke 44:2814-2820, Merwick, A.,et al, 2013
The Spectrum of Statin Myopathy
Curr Opin Rheumatol 25:747-752, Mohassel, P. & Mammen, A.L., 2013
Statin Use During Ischemic Stroke Hospitalization is Strongly Associated with Improved Poststroke Survival
Stroke 43:147-154, Flint, A.C.,et al, 2012
Sporadic Cerebral Amyloid Angiopathy Revisited: Recent Insights Into Pathophysiology and Clinical Spectrum
JNNP 83:124-137, Charidimou,A.,et al, 2012
Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack
NEJM 366:1914-1922;, Davis, S.M. & Donnan, G.A., 2012
High-Dose Statins should be Used in All Acute Ischemic Strokes
Stroke 43:1992-1993, 1996, Moonis, M., 2012
High-Dose Statins Should Only Be Used in Atherosclerotic Strokes
Stroke 43:1994-1995,1996, Furie, K.L., 2012
A Randomized, Double-Blind, Placebo Controlled Trial of Simvastatin to Treat Alzheimer Disease
Neurol 77:556-563, Sano, M.,et al, 2011
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes
Stroke 40:1405-1409, Amarenco,P.,et al, 2009
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Effect of Simvastatin on Cognitive Functioning in Children With Neurofibromatosis Type 1: A Randomized Controlled Trial
JAMA 300:287-294, Krab,L.C.,et al., 2008
Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women: Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study
Stroke 39:2444-2448, Goldstein,L.B.,et al., 2008
Statin Induced Myopathy
BMJ 337:1159-1162, Sathasivam,S. &Lecky,B., 2008
Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis
JAMA 297:1344-1353,1376, Crouse III,J.R.,et al, 2007
Antiplatelets, ACE Inhibitors, and Statins Combination Reduces Stroke Severity and Tissue At Risk
Neurol 66:1153-1158, Kumar,S.,et al, 2006
High-Dose Atorvastatin After Stroke or Transient Ischemic Attack
NEJM 355:549-559,613, The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, 2006
Discontinuation of Statin Treatment in Stroke Patients
Stroke 37:2640-2643, Endres,M. &Laufs,U., 2006
Expanding Indications for Statins in Cerebral Ischemia
Arch Neurol 62:67-72,23, Ovbiagele,B.,et al, 2005
Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease
Arch Neurol 62:753-757, Sparks,D.L.,et al, 2005
Statin Use and the Risk of Incident Dementia
Arch Neurol 62:1047-1051, Rea,T.D.,et al, 2005
Lipid-Lowering Agent Use at Ischemic Stroke Onset is Associated with Decreased Mortality
Neurol 65:253-258, Elkind,M.S.V.,et al, 2005
Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90056 Participants in 14 Randomised Trials of Statins
Lancet 366:1267-1278, Cholesterol Treatment Trialists (CTT) Collaborators, 2005
Statins Are Associated With Better Outcomes After Carotid Endarterectomy in Symptomatic Patients
Stroke 36:2072-2076,2058, Kennedy,J.,et al, 2005
Lipid Lowering Agents Are Associated With a Slower Cognitive Decline in Alzheimers Disease
JNNP 76:1624-1629, Masse,I.,et al, 2005
Effects of Cholesterol-lowering with Simvastatin on Stroke and Other Major Vascular Events in 20 536 People with Cerebrovascular Disease or Other High-Risk Conditions
Lancet 363:757-767, Heart Protection Study Collaborative Group, 2004
Favorable Outcome of Ischemic Stroke in Patients Pretreated with Statins
Stroke 35:1117-1123, Marti-Fabregas,J.,et al, 2004
Oral Simvastin Treatment in Relapsing-Remitting Multiple Sclerosis
Lancet 363:1607-1608,1570, Vollmer,T.,et al, 2004
Determination of Lipid Profiles and Use of Statins in Patients With Ischemic Stroke or Transient Ischemic Attack
Stroke 34:105-110, Lalouschek,W.,et al, 2003
Should I Start All My Ischaemic Stroke and TIA Patients on a Statin, an ACE Inhibitor, a Diuretic, and Aspirin Today?
JNNP 74:1461-1464, Sandercock,P.A.G., 2003
AAC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Stroke 33:2337-2341, Pasternak,R.C.,et al, 2002
Suppression of Recurrent Transient Ischemic Attacks by a Statin Agent
Neurol 56:531-532, Alberts,M.J., 2001
HMG-CoA Reductase Inhibitors (Statins)
Neurol 54:790-795, Hess,D.C.,et al, 2000
Statins and the Risk of Dementia
Lancet 356:1627-1631, Jick,H.,et al, 2000
An Overview of Acute Stroke Therapy
Arch Int Med 160:3196-3206, Fisher,M. & Schaebitz,W., 2000
Neuroprotective Properties of Statins in Cerebral Ischemia and Stroke
Stroke 30:1969-1973, Vaughan,C.J.&Delanty,N., 1999
Vascular Effects of Statins in Stroke
Stroke 28:2315-2320, Delanty,N.&Vaughan,C.J., 1997